BioNTech Secures CureVac Acquisition in Landmark mRNA Deal
Published on 11/27/2025 at 11:41 | Redaktion boerse-global.de
The German biotechnology firm BioNTech is on the verge of a significant strategic achievement, having successfully navigated the primary hurdle for its proposed acquisition of rival CureVac. An overwhelming majority of CureVac shareholders have given their approval, paving the way for BioNTech to integrate a promising portfolio of mRNA technologies and product candidates. Despite this positive development, the market’s initial reaction has been muted, raising questions about whether investors are overlooking the long-term potential of this consolidated entity.
A strong signal of confidence has emerged from the institutional investment community. Franklin Resources, a major US asset manager, substantially increased its stake in BioNTech by 76.8 percent. This move brings its total Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
